Two hundred CEE sites. Thousands of patients. Strong outcomes data. The US value-analysis committee files the device as untested. CEE deployment depth is invisible to US procurement scoring. The procurement scoring reads a different evidence stack.
UNCOUNTED.
If two hundred CEE sites does not register and one US pilot site does, the US procurement reading function is the issue, not the product.
CEE medtech evaluation is structured around clinical literature, CE-mark history, named-site adoption across CEE health systems, and national-payer reimbursement decisions. A device with deep CEE penetration reads as field-proven and well-supported. Procurement and clinical evaluation are tightly coupled in the CEE health systems. The Austrian medtech firm with broad CEE deployment carries strong evidence at home and across the region.
US IDN procurement evaluation is structured around the procurement function rather than the clinical function. The value-analysis committee scores on six US-readable signals: FDA pathway and clearance status, GPO contract availability, CMS coding and reimbursement clarity, US clinical evidence with US sites and US authors, US KOL adoption, and total cost of care impact in US accounting language. CEE clinical literature, while substantive, is not weighted against any of these six. The Austrian file led by CEE depth without the US-readable signals is filed under untested.
Per Roland Berger medtech outlook and IMAP life sciences M&A report, US IDN procurement scoring weights US-site clinical data and US-coded cost-of-care framing over equivalent CEE or European data. Reuters US hospital procurement coverage 2024-2026 documents the tightening of total cost of care framing across major US IDNs.
The fix is the same as for other European medtech files, with a specific note on CEE. CEE deployment data must be restated in US-readable form, with TCO modelling and US accounting language. Where US clinical sites do not yet exist, one US site has to be stood up. The US channel structure has to be built: GPO contract relationship, CMS coding documentation, FDA status restated, US KOL strategy. 6 signals, placed where US procurement reads them.
If you placed your CEE deployment number next to a US-domestic medtech's single US clinical site report tomorrow, which one does the US procurement officer score higher?
"Two hundred CEE sites is real. The US procurement officer scores one US site higher. Build the US site."House reading on Austrian medtech US entry
Stage one: read the file against the six signals. Score the US-facing materials against FDA pathway and status, GPO contract availability, CMS coding and reimbursement clarity, US clinical evidence with US sites and US authors, US KOL adoption, and total cost of care impact in US accounting language. Name every signal that is absent. CEE deployment numbers are kept as support, not as lead.
Stage two: rebuild the file and anchor one US site. Restructure the US-facing surface and the value-analysis dossier to lead with the six signals. Anchor one US clinical site with named US investigators producing US-published outcome data, even in modest patient numbers. Build a TCO model in US accounting language that translates the CEE outcome data into IDN-relevant savings.
Stage three: brief the US channel and the value-analysis committee. The US sales team is briefed on how to present the six signals in the VAC meeting. The IDN value-analysis committee is approached with a dossier structured around their reading order. The GPO outreach is restarted with a contract-ready package. The CEE deployment data is presented as supportive geographic depth rather than as the lead claim.
This work fits inside a Market Entry Sprint (six to ten weeks, one IDN segment, one device line), a Cross-Border Build (three to six months, full US procurement and channel rebuild), or a Group Partnership (monthly retainer, twelve-month minimum, for groups with multiple US-facing medtech lines). Pricing is confirmed in discovery, not on the public site.
| Before rebuild (CEE register) | After rebuild (US procurement register) |
|---|---|
| Lead signal: CEE deployment count and CE-mark | Lead signal: FDA status, GPO contract, CMS coding visible |
| Clinical evidence: CEE sites and CEE authors | Clinical evidence: one named US site, US authors, US-published |
| Cost narrative: device price comparison | Cost narrative: TCO model in US accounting language |
| KOL strategy: CEE-led | KOL strategy: US-named, US-society-aligned |
| Pilot expansion: zero | Pilot expansion: IDN-wide on the strength of the rebuilt file |
| VAC outcome: filed untested | VAC outcome: scored in the evaluation set, contract path open |
File first, US site second, channel third. CEE deployment is the support. The US site is the lead.
"US IDN procurement scoring has become more disciplined around US-site clinical evidence and US-coded cost-of-care framing. European and CEE clinical depth remain supportive but no longer carry the file on their own."
"We were testing demand and got polite signals back. The hardest part wasn't the build, it was figuring out which signal was real and which was just everyone being friendly because we were the new firm in the room."
US integrated delivery network procurement reads a specific evidence stack: FDA pathway and clearance status, GPO contract availability, CMS coding and reimbursement, US clinical evidence with US sites and US authors, US KOL adoption, and total cost of care impact in US accounting language. CEE deployment data is read as supportive geographic experience but does not substitute for any of the six US-readable signals. A Vienna medtech with 200 CEE sites and zero US-readable evidence reads as untested in the US procurement scoring.
Six things: FDA status with the specific clearance pathway, GPO contract availability, CMS coding and reimbursement clarity, US clinical evidence with US sites and US authors, US KOL adoption, and total cost of care impact in US accounting language. CEE clinical literature and CE-mark are read as supportive only. The Austrian medtech file led by CEE deployment depth without these six is filed under untested.
Not useless. Useful in support, not as the lead. CEE deployment numbers tell the US procurement reader that the device is field-proven in volume. That is helpful background. It does not score the procurement. The fix is to restate CEE data in the US format with TCO modelling, while building the US clinical site presence and the GPO contract conversation in parallel.
Less than firms expect, more than firms typically provide. One named US clinical site with US investigators producing US-published outcome data, even in modest patient numbers, moves the file out of untested. Combined with a TCO model in US accounting language and a structured GPO outreach, the device is back in the evaluation set within one VAC cycle. Per Roland Berger medtech outlook, US procurement readers explicitly weight one US clinical site above significant European or CEE site numbers for first-read scoring.
Inquiry through the contact form and a discovery conversation. Send the current US-facing materials, the FDA status and pathway document, the CEE deployment and clinical pack, the last three IDN evaluations, and the GPO outreach record. Response within one business day. Pricing confirmed in discovery, not on the public site.
No legal services. No FDA submissions, no 510(k), De Novo, or PMA filings. No CE-mark or notified-body work. No clinical trial design, IRB submissions, or regulatory medical writing. No GPO contract negotiation. No CMS coding or reimbursement filings. No HIPAA, SaMD, or device cybersecurity certification. No US, Austrian, or other-jurisdiction entity formation. No US tax structuring. No US banking introductions. No fiduciary services. No IP filing. No M&A advisory. The clinical and regulatory substance sits with regulatory counsel, clinical research organisations, and reimbursement consultants on both sides of the corridor. The firm rebuilds the commercial and procurement-facing surface that runs alongside the regulatory and clinical file. When a marketing decision touches clinical, regulatory, or reimbursement implications, the firm flags it and defers before execution.